Home > Browse Issues > Vol.38 No.11
Signaling Pathways of Immune Checkpoint Protein PD-1 and Cancer Immunotherapy
Chen Jie1, Ding Qian1, Chen Shuqing2, Zhan Jinbiao1*
1Department of Biochemistry, School of Medicine, Zhejiang University, Hangzhou 310058, China;
2College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
2College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
Abstract: PD-1 (programmed death-1) belongs to B7-CD28 (B7 family-cluster of differentiation 28) dependent Ig-like family. As a suppressive receptor， PD-1 plays pivotal roles in signal transduction of T cells. The blockage of the signaling between PD-1 and its ligand PD-L1(programmed death-1 ligand-1) will promote the T cells proliferation and differentiation and conseguently activate immune responses against tumor cells. Binding to its another ligand PDL2，PD-1 not only plays a key role in tumor immunity， but also plays important roles in asthma， allergic reaction and so on. This review focused on the signaling pathways of PD-1 and its ligands， as well as antibody inhibitors and the clinical application in cancer immunotherapy.
CN
EN